April 01, 2025

Second-Generation Anti-VEGF Agents for Neovascular AMD

Second-generation anti-VEGF agents were developed to extend durability, improve fluid reduction, and reduce the need for injections while maintaining visual outcomes and safety. Brolucizumab 6 mg (Beovu; Novartis), faricimab-svoa 6 mg (Vabysmo; Genentech), and aflibercept 8 mg (Eylea HD; Regeneron) are FDA-approved second-generation anti-VEGF agents that have reshaped the treatment landscape for nAMD.

Retinal Physician

April 01, 2025

Coding Q&A: Coding Guidelines for Wet AMD

Ensure compliance and prompt payment by using proper ICD-10-CM codes for diagnosing patients with exudative age-related macular degeneration (wet AMD). Learn the guidelines for coding specific eye conditions and disease stages.

Retinal Physician

April 01, 2025

Clinical Trial Update April 2025

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

Retinal Physician

April 01, 2025

Novel Therapeutics for Neovascular AMD

Multiple trials of molecules targeting the larger anti-VEGF family and other pathways have been initiated, which may translate into a future of durable and efficacious therapies for neovascular age-related macular degeneration.

Retinal Physician

April 01, 2025

Refractive Error Management During Anti-VEGF Therapy

Refractive errors are often inadequately addressed in patients undergoing anti-VEGF treatment, yet correction of these errors could play a crucial role in maximizing visual acuity in patients with diabetic macular edema or neovascular age-related macular degeneration.

Retinal Physician

April 01, 2025

Detecting Diagnostic and Prognostic Biomarkers of Geographic Atrophy

This is the first in a series focusing on the diagnosis and treatment of geographic atrophy.

Optometric Management

March 31, 2025

What’s Next for Myopia Management

Consensus report provides strategies that more accurately reflect the possible severity of disease.

Conexiant

March 31, 2025

Opthea Suspends ShORe, COAST Trials

Top-line data from the phase 3 trials of sozinibercept showed that the nAMD treatment failed to meet its primary BCVA endpoints in both studies.

Conexiant

March 27, 2025

AI Accuracy Boosted by Synthetic Retinal Images

Researchers found that the convolutional neural network outperformed ophthalmologists in disease classification accuracy. Generated images improved its accuracy further.

Conexiant